Orthovisc Injections denied? Start your appeal.
Start with the reason on your denial notice. Check your plan’s appeal route, then gather the records that answer the specific coverage rule.
No account or payment to check your route. You confirm the plan facts; published review outcomes do not predict your result.
Free evidence checklist for knee osteoarthritis
What to gather for a knee injection appeal
Use the published decisions to ask better questions, then answer the exact rule in your denial. Bring this checklist to your treating clinician; it does not tell you which treatment to choose.
Download blank checklist (.txt)- The denial and the applicable rule. Keep the complete notice, notice date, filing deadline, recipient, and the exact plan policy or criterion cited. Ask which benefit covers the injection and whether the dispute is medical necessity, a preferred product, repeat timing, or a billing issue.
- Diagnosis, knee, and functional limits. Ask the clinician to identify the affected knee, diagnosis, relevant imaging report, and how pain limits walking, standing, or other daily activities. Do not infer a diagnosis from pain alone.
- Conservative care already tried. List each treatment, dates, duration, response, and adverse effects. Include non-drug approaches and medicines where relevant. Ask the clinician to explain any contraindication instead of treating a contraindicated therapy as a required trial.
- Why this product and this request. Ask the prescriber to answer the actual denial criterion, explain the individual rationale, and check the requested dose and schedule against current product labeling. Approval of one hyaluronic-acid product does not establish coverage for every product.
- If this is a repeat series. Record prior injection dates, which knee was treated, measurable pain and function changes, when symptoms returned, and why the timing satisfies the applicable policy. A first series and a repeat series can have different criteria.
- A complete submission record. Match each disputed criterion to an attachment. Confirm the governing appeal route, send it using the notice instructions, and keep the submission receipt. Ask the clinician about an urgent review if waiting could seriously harm health.
Coverage criteria and clinical guidance are different
For example, Medicare LCD L39260 requires documented symptomatic knee osteoarthritis, radiographic support, a qualifying conservative-care history, and other criteria. Repeat treatment has separate requirements, including a prior response and a minimum interval. This is a local policy: verify the contractor, service date, and complete rule before relying on it.
AAOS does not recommend hyaluronic-acid injections for routine knee osteoarthritis use. Favorable historical reviews do not erase that limitation. Ask the clinician to explain the individual rationale and address the plan's criteria. For Monovisc, consult the FDA approval record and current labeling; FDA approval is not a coverage guarantee.
U.S. self-help preparation for knee osteoarthritis injection denials; not medical or legal advice. The historical California review rate is not your chance of success. L39260 is a local Medicare policy, not a nationwide rule for every plan. Confirm contractor jurisdiction, service date, and the policy in your notice. Clinical guidance and FDA labeling do not guarantee insurance coverage. Sources reviewed 2026-09-05.
- FDA: Monovisc approval record and labeling
- CMS: local coverage determination L39260
- AAOS: knee osteoarthritis clinical guideline
The download is a blank, printable worksheet. Fill it in privately; nothing you write in the downloaded file is sent to Coverage Rights.
In the California DMHC record, independent physician reviewers decided 223 published external-review cases involving Orthovisc Injections and overturned the plan’s denial in 76.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 119 | 84.9% |
| Knee Osteoarthritis | 51 | 58.8% |
| Osteoarthritis | 15 | 73.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 205 | 81.5% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 18 | 22.2% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Orthovisc injections for both knees (3 for each knee). The Health Plan has denied this request indicating that the requested procedures are not medically necessary for treatment of the enrollee’s osteoarthritis of the knees. A review of the record indicates that the enrollee has been diagnosed with osteoarthritis of the knees. The enrollee reported having bilateral knee pain. Physical examination findings included left knee medial and lateral joint line tenderness. Left knee range of motion was 0-130 degrees. Left knee strength was rated as 5 of 5. Full range of motion was noted in the right knee with no tenderness to palpation.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Orthovisc injections to the knees. The Health Plan has denied this request indicating that the requested procedure is not medically necessary for treatment of the enrollee’s bilateral knee osteoarthritis. A review of the record indicates that the enrollee has been diagnosed with bilateral knee osteoarthritis. In a report, the enrollee’s provider noted knee pain. The provider noted prior viscosupplementation provided 4 to 4.5 months of significant improvement. The enrollee’s provider has recommended Orthovisc injections to the knees for the enrollee.Four prior series of injections resulted in significant benefit to the enrollee.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Orthovisc injections to the left shoulder, once a week for four weeks. The patient was being treated for primary localized osteoarthritis of the shoulder. The patient underwent a left shoulder arthroscopy. The patient reported pain and discomfort at the anterior aspect of the left shoulder due to arthritic changes. The patient attempted treatment with physical therapy exercises without success. Upon physical examination, the medical records indicated that the left shoulder demonstrated near normal range of motion with improved rotator cuff strength. The provider recommended a hyaluronic acid injection series to treat the arthritic changes seen in the operative site in the left shoulder.
Findings: The physician reviewer found that the patient has history of right knee osteoarthritis who is requesting reimbursement for Orthovisc injections. In the medical literature, researchers concluded that hyaluronic acid was the best pharmacologic intervention for knee osteoarthritis in their meta-analysis of 137 studies with 33,243 participants. Hyaluronic acid was found to be better than injected placebo or injected corticosteroids. All treatments except acetaminophen showed clinically significant improvement from baseline pain. In addition, another research reported that repeated cycles of intra-articular sodium hyaluronate treatment to delay time to total knee replacement in patients with knee osteoarthritis, which failed conservative treatment, was efficacious during a 54-month follow-up period.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Orthovisc Injections, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY